Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study
Therapeutic Apheresis and Dialysis · 2026-08 · 30 (4) · 476-481
DOI: 10.1002/1744-9987.70164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 22.06.2026. Verfasst von Kunihiro Ishioka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan. Hauptthemen laut MEDLINE: Renal Dialysis, Blood Component Removal, Lipoproteins, LDL, Ischemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Chronic limb‐threatening ischemia (CLTI) is a severe form of lower‐extremity artery disease characterized by distal lesions and microcirculatory impairment, limiting revascularization efficacy. Rheocarna is a direct hemoperfusion low‐density lipoprotein (LDL) adsorption device with potential rheological and anti‐inflammatory benefits. The real‐world effectiveness of Rheocarna in patients with advanced CLTI undergoing hemodialysis (HD) remains unclear. This study evaluated clinical outcomes of Rheocarna therapy in patients with CLTI undergoing HD.
Methods
We retrospectively reviewed 31 patients undergoing HD (mean [±SD] age 67 ± 11 years) with CLTI treated with Rheocarna at a single center. Primary outcomes were ulcer healing at 6 months and amputation‐free survival (AFS) at 1 year, with baseline characteristics compared between healed and non‐healed groups.
Results
At 6 months, the ulcer healing, major amputation, and mortality rates were 25.8%, 35.5%, and 22.6%, respectively. The 1‐year AFS rate was 40%. The mean ankle–brachial index significantly improved from 1.00 ± 0.17 to 1.07 ± 0.15 ( p = 0.041).
Conclusion
Rheocarna may support wound healing and limb salvage in patients with CLTI undergoing HD; however, its clinical effectiveness appears limited in advanced disease stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan.
Zitieren
APA
Ishioka, K., Ohtake, T., Ohmori, K., Shibuya, C., Tsukahara, T., Yamano, M., Mochida, Y., Oka, M., Maesato, K., Tsukamoto, Y., Moriya, H., Hidaka, S., & Kobayashi, S. (2026). Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study. Therapeutic Apheresis and Dialysis, 30(4), 476-481. https://doi.org/10.1002/1744-9987.70164
Vancouver
Ishioka K, Ohtake T, Ohmori K, Shibuya C, Tsukahara T, Yamano M, et al. Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study. Therapeutic Apheresis and Dialysis. 2026;30(4):476-481. doi:10.1002/1744-9987.70164
BibTeX
@article{Ishioka2026,
author = {Ishioka, Kunihiro and Ohtake, Takayasu and Ohmori, Kei and Shibuya, Chika and Tsukahara, Tomoki and Yamano, Mizuki and Mochida, Yasuhiro and Oka, Machiko and Maesato, Kyoko and Tsukamoto, Yusuke and Moriya, Hidekazu and Hidaka, Sumi and Kobayashi, Shuzo},
title = {Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
volume = {30},
number = {4},
pages = {476--481},
doi = {10.1002/1744-9987.70164}
}
EUVIMED